Semi-Automation of a Non-Radioactive Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) Assay: Part I - Automation of a Bioluminescent ADCC Procedure with a Microplate Pipetting System

This application note describes the use of a non-radioactive, bioluminescent Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) assay. The protocol is a simple sequential addition of reagents and cells that can be readily automated with a simple, inexpensive pipetting station. The study demonstrates the semi-automation of the ADCC assay using Daudi cells, rituximab (monoclonal antibody used in the drug Rituxan) and freshly isolated primary human NK cells.